Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial (P4.384)

Conclusions:In the ORATORIO trial, ocrelizumab increased by approximately 3-fold the proportion of patients with NEPAD vs placebo, as measured by the combination of no evidence of progression, no relapse and no MRI activity. NEPAD may represent a useful composite outcome to assess the absence of clinical and MRI features of disease progression and activity in patients with PPMS.Study Supported by:Sponsored by F. Hoffmann-La Roche Ltd.Disclosure: Dr. Wolinsky has received personal compensation for activities with AbbVie, AcademicCME, Alkermes, Bayer HealthCare, Forward Pharma A/S, Novartis, Roche/Genentech, Sanofi Genzyme, Takeda, Teva Pharmaceuticals, and WebMD. Dr. Wolinsky has received royalty payments from University of Texas Health Science Center at Houston. Dr. Montalban has received personal compensation for activities with Almirall, Bayer, Biogen, Celgene, Sanofi Genzyme, Merck, Novartis, Roche, and Teva Pharmaceutical. Dr. Kappos has reveived personal compensation for activities with University Hospital Basel as an advisory board member. Dr. Kappos has received research support from Swiss Multiple Sclerosis Society, Swiss National Research Foundation, European Union, Gianni Rubatto Foundation, Novartis Research Foundation, and Roche Research Foundation. Dr. Hauser has received personal compensation for activities with Annexon, Symbiotix, Bionure as a scientific advisory board member and from F. Hoffmann-La Roche Ltd. Dr. Giovannoni has received personal compensation f...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Wolinsky, J., Montalban, X., Kappos, L., Hauser, S., Giovannoni, G., de Seze, J., Bar-Or, A., Masterman, D., Bernasconi, C., Wei, W., Garren, H., Chin, P., Belachew, S., Arnold, D. Tags: No Evidence of Disease Activity in Multiple Sclerosis Source Type: research